Two weeks after a positive FDA advisory panel hearing, Genzyme General and partner BioMarin Pharmaceutical Inc. said Wednesday the agency issued a complete response letter for Aldurazyme without requesting additional clinical data for final approval. (BioWorld Today) Read More